BNP Paribas Asset Management
ONC

BNP Paribas Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

BNP Paribas Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
37,070
+3,342
+10% +$985K 0.01% 729
2026
Q1 		$10M Sell
33,728
-337
-1% -$109K 0.01% 697
2025
Q4 		$10.3M Buy
+34,065
New +$11.2M 0.01% 675
2025
Q2 		– Sell
-78,388
Closed -$21M – 2092
2025
Q1 		$21M Sell
78,388
-1,656
-2% -$387K 0.06% 332
2024
Q4 		$14.8M Sell
80,044
-17,851
-18% -$3.65M 0.04% 395
2024
Q3 		$22M Buy
97,895
+266
+0.3% +$47.9K 0.05% 293
2024
Q2 		$13.9M Sell
97,629
-444
-0.5% -$68.4K 0.04% 361
2024
Q1 		$15.3M Sell
98,073
-4,897
-5% -$789K 0.04% 350
2023
Q4 		$18.6M Buy
102,970
+7,130
+7% +$1.29M 0.05% 310
2023
Q3 		$17.2M Buy
95,840
+1,832
+2% +$362K 0.05% 311
2023
Q2 		$16.8M Buy
94,008
+837
+0.9% +$193K 0.05% 311
2023
Q1 		$20.1M Sell
93,171
-1,686
-2% -$404K 0.07% 292
2022
Q4 		$20.9M Buy
94,857
+18,217
+24% +$3.34M 0.07% 288
2022
Q3 		$10.3M Sell
76,640
-1,622
-2% -$279K 0.04% 405
2022
Q2 		$12.7M Sell
78,262
-88,622
-53% -$13.8M 0.05% 366
2022
Q1 		$31.5M Buy
166,884
+966
+0.6% +$205K 0.11% 219
2021
Q4 		$45M Buy
165,918
+8,993
+6% +$3.04M 0.15% 166
2021
Q3 		$57M Buy
156,925
+91,527
+140% +$29.9M 0.21% 119
2021
Q2 		$22.4M Buy
+65,398
New +$21.7M 0.08% 289
2020
Q4 		– Sell
-11,893
Closed -$3.41M – 859
2020
Q3 		$3.41M Buy
11,893
+1,018
+9% +$239K 0.02% 527
2020
Q2 		$2.05M Buy
10,875
+208
+2% +$33.9K 0.01% 556
2020
Q1 		$1.31M Buy
10,667
+2,038
+24% +$319K 0.01% 584
2019
Q4 		$1.43M Buy
8,629
+2,021
+31% +$336K 0.01% 628
2019
Q3 		$809K Buy
6,608
+448
+7% +$59.5K 0.01% 697
2019
Q2 		$764K Buy
6,160
+918
+18% +$117K 0.01% 693
2019
Q1 		$692K Hold
5,242
– – 0.01% 758
2018
Q4 		$718K Buy
+5,242
New +$695K 0.01% 748

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BNP Paribas Asset Management's ONC Position: Q2 2026 in Review

BNP Paribas Asset Management increased its BeOne Medicines Ltd (ONC) stake by 9.9% in Q2 2026, buying an estimated $985K and bringing the position to 37,070 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #729.

BNP Paribas Asset Management first reported a position in ONC in Q4 2018 and has held it in 27 quarters since. The position peaked at $57M in Q3 2021. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • BNP Paribas Asset Management held 37,070 shares of BeOne Medicines Ltd worth $10.6M as of Q2 2026.
  • BNP Paribas Asset Management bought 3,342 BeOne Medicines Ltd shares in Q2 2026, an estimated $985K.
  • BeOne Medicines Ltd made up 0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #729 holding.
  • BNP Paribas Asset Management first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 27 quarters since.
  • BNP Paribas Asset Management's BeOne Medicines Ltd position peaked at $57M in Q3 2021.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.